A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation
Clinical trial NCT03556332 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03556332
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-07-02
- Primary completion
- 2027-07-01
- Enrollment
- 41
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.